Table 2.
All patients | ER-Positive patients | ||||
---|---|---|---|---|---|
Variable | p value | OR (95% CI) | Variable | p value | OR (95% CI) |
Age at diagnosis | 0.00040 | 0.97 (0.96–0.99) | Age at diagnosis | 0.001 | 0.97 (0.96–0.99) |
Tumor size (T3 and T4 vs. T1 and T2) | 0.00262 | 2.09 (1.29–3.38) | Tumor size (T3 and T4 vs. T1 and T2) | 0.195 | 1.45 (0.83–2.45) |
Histological typea | 0.00513 | Histological type | |||
ILC versus IDC | 0.00968 | 0.44 (0.23–0.82) | ILC versus IDC | 0.011 | 0.42 (0.21–0.81) |
Other type versus IDC | 0.12139 | 1.59 (0.88–2.86) | Other type versus IDC | 0.075 | 1.76 (0.94–3.30) |
PR status (positive vs. negative) | 0.00001 | 2.92 (1.81–4.73) | Race | ||
- | - | - | Black/African American versus White | 0.285 | 1.35 (0.78–2.34) |
- | - | - | Asian versus White | 0.031 | 2.29 (1.08–4.86) |
Significant p values are shown in bold.
CI confidence interval, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, OR odds ratio, PR progesterone receptor.
aOther category includes rare histological types, such as metaplastic and medullary tumors.